Patents by Inventor Antonius J. M. Berns

Antonius J. M. Berns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transgenic mice depleted in a mature lymphocytic cell-type
    Patent number: 5591669
    Abstract: Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprised is a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 7, 1997
    Assignee: GenPharm International, Inc.
    Inventors: Paulus J. A. Krimpenfort, Antonius J. M. Berns
  • Transgenic mice depleted in mature T-cells and methods for making transgenic mice
    Patent number: 5434340
    Abstract: Transgenic mice having a phenotype characterized by the substantial absence of mature T lymphocytes otherwise naturally occurring in said mice. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the T lymphocyte which is depleted. The transgene comprises a DNA sequence encoding a T cell receptor polypeptide variant which inhibits maturation of the T lymphocyte.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: July 18, 1995
    Assignee: GenPharm International, Inc.
    Inventors: Paulus J. A. Krimpenfort, Antonius J. M. Berns
  • Transgenic mice depleted in mature T-cells and methods for making transgenic mice
    Patent number: 5175384
    Abstract: Transgenic mice having a phenotype characterized by the substantial absence of mature T lymphocytes otherwise naturally occurring in said mice. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the T lymphocyte which is depleted. The transgene comprises a DNA sequence encoding a T cell receptor polypeptide variant which inhibits maturation of the T lymphocyte.
    Type: Grant
    Filed: December 5, 1988
    Date of Patent: December 29, 1992
    Assignee: GenPharm International
    Inventors: Paulus J. A. Krimpenfort, Antonius J. M. Berns
  • Deletion mutant of pseudorabies virus and vaccine containing said virus
    Patent number: 5028426
    Abstract: A thymidine kinase deficient live deletion mutant of pseudorabies virus is provided. The mutant, designated PRV783 was derived from the live deletion mutant strain 2.4N3A by deleting a 19 bp sequence from the BamHI fragment 11 of strain 2.4N3A into which had been inserted an EcoRI restriction site at a unique cleavage site in fragment 11 for the restriction endonuclease XhoI. The 19 bp deletion encompasses the inserted EcoRI site in fragment 11 of strain 2.4N3A. PRV783 is useful for preparing vaccine compositions to immunize susceptible animals against infection by pseudorabies virus.
    Type: Grant
    Filed: July 28, 1987
    Date of Patent: July 2, 1991
    Assignee: Centraal Diegeneeskundig Instituut
    Inventors: Antonius J. M. Berns, Arnold L. J. Gielkens, Robertus J. M. Moormann
  • Deletion mutant of a herpesvirus and vaccine containing said virus
    Patent number: 4680176
    Abstract: The invention relates to live deletion mutants of a herpesvirus, especially of Pseudorabies virus. The genomes of the mutants differ from the genomes of the parent strain by the presence of one or more deletions selected from a deletion in the inverted repeats, a deletion in the unique sequence, and a deletion in the thymidine kinase gene.The new deletion mutants are avirulent, do not induce latent infections, are stable and possess good immunogenic properties.The invention also relates to vaccines containing the new mutant strains.
    Type: Grant
    Filed: October 12, 1984
    Date of Patent: July 14, 1987
    Assignee: Centraal Diergeneeskundig Instituut
    Inventors: Antonius J. M. Berns, Arnold L. J. Gielkens
  • Deletion mutant of a herpesvirus and vaccine containing said virus
    Patent number: RE33772
    Abstract: The invention relates to live deletion mutants of a herpesvirus, especially of Pseudorabies virus. The genomes of the mutants differ from the genomes of the parent strain by the presence of one or more deletions selected from a deletion in the inverted repeats, a deletion in the unique sequence, and a deletion in the thymidine kinase gene.The new deletion mutants are avirulent, do not induce latent infections, are stable and possess good immunogenic properties.The invention also relates to vaccines containing the new mutant strains.
    Type: Grant
    Filed: August 2, 1988
    Date of Patent: December 17, 1991
    Assignee: Centraal Diergeneeskundig Instituut
    Inventors: Antonius J. M. Berns, Arnold L. J. Gielkens